ArticleDigestive diseases and sciences2026
Branched-Chain Amino Acid Supplementation and Clinical Outcomes in Liver Cirrhosis: A Propensity Score-Matched Multicenter Retrospective Cohort Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026.Clinical and molecular hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBranched-Chain Amino Acid (BCAA) supplementation has shown benefits in reducing liver cirrhosis complications, improving survival, and potentially lowering hepatocellular carcinoma risk, but evidence on long-term outcomes remains limited. This real-world study evaluates clinical outcomes of liver cirrhosis patients receiving BCAA supplementation.
methodsThis retrospective cohort study used the TriNetX US Collaborative Network to identify liver cirrhosis patients aged ≥ 18 years, stratified by BCAA supplementation after diagnosis. Propensity score matching (PSM) balanced cohorts by demographics, body mass index, Model for End-Stage Liver Disease (MELD) score components, and baseline history of cirrhosis complications, including hepatic encephalopathy (HE), sarcopenia, spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), and falls. Composite and individual outcomes within 5 years were assessed using odds ratios (OR) with 95% confidence intervals (CI).
resultsAmong 2,176 matched patients per group, BCAA supplementation was associated with lower rates of the composite outcome (OR 0.81, 95% CI: 0.71-0.92), HE (OR 0.63, 95% CI: 0.49-0.79), SBP (OR 0.77, 95% CI: 0.60-0.99), falls (OR 0.64, 95% CI: 0.53-0.78), all-cause emergency room visits (OR 0.56, 95% CI: 0.50-0.64), and hospitalizations (OR 0.68, 95% CI: 0.60-0.76). Liver transplantation occurred more frequently in the BCAA group (OR 1.49, 95% CI: 1.08-2.06). Sarcopenia rates were similar (OR 1.00, 95% CI: 0.42-2.41), while AKI was slightly more frequent (OR 1.13, 95% CI: 1.00-1.28). Subgroup analysis showed greater benefit in viral hepatitis-associated (OR 0.69, 95% CI: 0.53-0.90) and alcohol-associated cirrhosis (OR 0.73, 95% CI: 0.60-0.89), compared to MASLD (OR 0.81, 95% CI: 0.60-1.08).
conclusionBCAA supplementation was associated with significant reductions in several cirrhosis-related complications, with most benefits observed in viral hepatitis-associated and alcohol-associated cirrhosis.
Indexed as
Identifiers
40762759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.